ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031

ABL Diagnostics and CDL Pharma Secure a Multi-year International Contract of up to €2.7 Million Through 2031

Regulatory News:

ABL Diagnostics (FR001400AHX6 – “ABLD”) announces the signing of a multi-year contract with a European pharmaceutical company in the field of neurodegenerative diseases. The contract relates to services operated by CDL Pharma and distributed by ABL Diagnostics.

This partnership is part of an international clinical program involving 30 centers across 11 countries in North America, Europe, and Asia, reflecting the Group’s ability to support global multicenter studies.

The agreement includes an initial payment exceeding €100,000 upon signature, as well as a total contractual value that could reach approximately €2.7 million through 2031. Revenue will be recognized progressively based on the performance of the services under the contract and remains dependent on the effective progress of the clinical program.